Treats dementia of the Alzheimer's type. ANDA 200292, held by Prinston Inc. Donepezil Hydrochloride.
As of Nov 16, 2026, ANDA 200292 (Donepezil Hydrochloride), held by Prinston Inc, was first approved by FDA on May 31, 2011, with 6 approved supplements and 0 published complete response letters.
Donepezil hydrochloride is indicated for the treatment of dementia of the Alzheimer's type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's disease.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 31, 2011 | Original application | Approved | None posted |
| Donepezil Hydrochloride5MG · tablet;oral | Donepezil Hydrochloride | Rx |
| Donepezil Hydrochloride10MG · tablet;oral | Donepezil Hydrochloride | Rx |
| Sep 17, 2024 | Supplement 9Labeling · Standard review | Approved | None posted |
| Sep 17, 2024 | Supplement 11Labeling · Standard review | Approved | None posted |
| Sep 21, 2020 | Supplement 8Labeling · Standard review | Approved | None posted |
| Nov 20, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 20, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Apr 6, 2012 | Supplement 1Labeling | Approved | None posted |
| May 31, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters